Tocilizumab: is there life beyond anti-TNF blockade?

被引：10

作者：

Alves, J. D. ^{[1
,2
]}

Marinho, A. ^{[3
]}

Serra, M. J. ^{[4
]}

机构：

[1] Univ Nova Lisboa, Fac Med Sci, Dept Pharmacol, P-1169056 Lisbon, Portugal

[2] Fernando da Fonseca Hosp, Dept Med 4, Lisbon, Portugal

[3] Santo Antonio Hosp, Oporto, Portugal

[4] CUF Descobertas Hosp, Lisbon, Portugal

来源：

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE | 2011年 / 65卷 / 04期

关键词：

INTERLEUKIN-6 RECEPTOR INHIBITION; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; DISEASE-ACTIVITY; METHOTREXATE MONOTHERAPY; CONTROLLED-TRIAL; THERAPY; COMBINATION; ETANERCEPT; AGENTS;

D O I：

10.1111/j.1742-1241.2010.02612.x

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

P>Anti-TNF-alpha therapy has become the most effective biological treatment for rheumatoid arthritis. Despite having changed the prognosis of the disease establishing new targets for treatment strategy, there are several aspects that still remain unmatched. About 30% of the patients with rheumatoid arthritis have a less than satisfactory response to anti-TNF therapy, which has led the way for the pursuit of new targets and approaches to treatment. IL-6 is one of these alternative targets and data from the more recent clinical trials involving tocilizumab (an anti-IL-6 soluble receptor antibody) suggest advantages in relation to some clinical aspects which are not addressed by anti-TNF-alpha treatment.

引用

页码：508 / 513

页数：6

共 48 条

[1]

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score [J].

Aletaha, D ;

Nell, VP ;

Stamm, T ;

Uffmann, M ;

Pflugbeil, S ;

Machold, K ;

Smolen, JS .

ARTHRITIS RESEARCH & THERAPY, 2005, 7 (04) :R796-R806

[2]

Cancer Risk in Patients With Rheumatoid Arthritis Treated With Anti-Tumor Necrosis Factor α Therapies Does the Risk Change With the Time Since Start of Treatment? [J].

Askling, Johan ;

van Vollenhoven, Ronald F. ;

Granath, Fredrik ;

Raaschou, Pauline ;

Fored, C. Michael ;

Baecklund, Eva ;

Dackhammar, Christina ;

Feltelius, Nils ;

Coster, Lars ;

Geborek, Pierre ;

Jacobsson, Lennart T. ;

Lindblad, Staffan ;

Rantapaa-Dahlqvist, Solbritt ;

Saxne, Tore ;

Klareskog, Lars .

ARTHRITIS AND RHEUMATISM, 2009, 60 (11) :3180-3189

[3]

The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases [J].

Atzeni, Fabiola ;

Turiel, Maurizio ;

Caporali, Roberto ;

Cavagna, Lorenzo ;

Tomasoni, Livio ;

Sitia, Simona ;

Sarzi-Puttini, Piercarlo .

AUTOIMMUNITY REVIEWS, 2010, 9 (12) :835-839

[4]

Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry) [J].

Augustsson, J. ;

Neovius, M. ;

Cullinane-Carli, C. ;

Eksborg, S. ;

van Vollenhoven, R. F. .

ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (01) :126-131

[5]

The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].

Breedveld, FC ;

Weisman, MH ;

Kavanaugh, AF ;

Cohen, SB ;

Pavelka, K ;

van Vollenhoven, R ;

Sharp, J ;

Perez, JL ;

Spencer-Green, GT .

ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37

[6]

The Role of Anti-Tumor Necrosis Factor Receptor Agents in Cancer Survivors: Does the Risk Justify the Benefit? [J].

Chapman, Paul ;

Cranmer, Lee ;

Dixon, W. G. ;

Hyrich, K. L. ;

Patterson, John R. ;

Symmons, D. P. M. ;

Toporcer, Mary ;

Mastrangelo, Michael J. .

SEMINARS IN ONCOLOGY, 2010, 37 (01) :11-19

[7]

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial [J].

Clair, EWS ;

van der Heijde, DMFM ;

Smolen, JS ;

Maini, RN ;

Bathon, JM ;

Emery, P ;

Keystone, E ;

Schiff, M ;

Kalden, JR ;

Wang, B ;

DeWoody, K ;

Weiss, R ;

Baker, D .

ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3432-3443

[8]

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor [J].

Dayer, Jean-Michel ;

Choy, Ernest .

RHEUMATOLOGY, 2010, 49 (01) :15-24

[9]

Serious infection following anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis -: Lessons from interpreting data from observational studies [J].

Dixon, W. G. ;

Symmons, D. P. M. ;

Lunt, M. ;

Watson, K. D. ;

Hyrich, K. L. ;

Silman, A. J. .

ARTHRITIS AND RHEUMATISM, 2007, 56 (09) :2896-2904

[10]

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR) [J].

Dixon, W. G. ;

Hyrich, K. L. ;

Watson, K. D. ;

Lunt, M. ;

Galloway, J. ;

Ustianowski, A. ;

Symmons, D. P. M. .

ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (03) :522-528

← 1 2 3 4 5 →